Changes in Beneficial Ownership · 4
Kalaris Therapeutics, Inc.
KLRSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-06-03
- Issuer
- Kalaris Therapeutics, Inc.
- Issuer CIK
- 0001754068
- Trading symbol
- KLRS
Reporting owner 1
- Name
- Ferrara Napoleone
- Reporting owner CIK
- 0001744779
- Relationship
- Director
- Address
- C/O KALARIS THERAPEUTICS, INC., 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 4.72 | 2026-06-03 | A · Form 4 | 9,000 | A | 0 | [F1] | 2036-06-02 | Common Stock | 9,000 | 9,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.↩ 1
Signature 1
- Signed
- /s/ Brett Hagen, Attorney-in-Fact
- Date
- 2026-06-04
Company context
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.